Resources from the same session
CDK4-6 inhibitors in patients with early HR positive / HER2 negative breast cancer: Successes and failures
Presenter: G. Curigliano, IT
Session: Session 1 – CDK4-6 inhibitors in early breast cancer
Resources:
Slides
Webcast
Incorporating CDK 4-6 inhibitors in patients with high-risk HR positive/ HER2 negative early breast cancer: Challenging clinical scenarios with the use of PARP inhibitors and immune-checkpoint inhibitors
Presenter: D. Trapani, IT
Session: Session 1 – CDK4-6 inhibitors in early breast cancer
Resources:
Slides
Webcast